These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22245206)

  • 21. Impact of intensity-modulated radiation therapy as a boost treatment on the lung-dose distributions for non-small-cell lung cancer.
    Choi Y; Kim JK; Lee HS; Hur WJ; Chai GY; Kang KM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):683-9. PubMed ID: 15927412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative planning evaluation of intensity-modulated radiotherapy techniques for complex lung cancer cases.
    Yartsev S; Chen J; Yu E; Kron T; Rodrigues G; Coad T; Trenka K; Wong E; Bauman G; Dyk JV
    Radiother Oncol; 2006 Feb; 78(2):169-76. PubMed ID: 16413621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Are there any dosimetric advantages in using VMAT for treatment of locally advanced non-small cell lung cancer?].
    Rousseau D; Autret D; Krhili S; Yossi S; Dupas A; Edouard M; Mahé MA; Giraud P; Le Péchoux C; Cellier P; Denis F; Paumier A
    Cancer Radiother; 2012 Oct; 16(7):619-26. PubMed ID: 23089069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An accelerated radiotherapy scheme using a concomitant boost technique for the treatment of unresectable stage III non-small cell lung cancer.
    Izmirli M; Yaman F; Buyukpolat MY; Yoney A; Unsal M
    Jpn J Clin Oncol; 2005 May; 35(5):239-44. PubMed ID: 15886271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
    Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
    J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: practical implications of using a broad or sharp brush.
    Meijer G; Steenhuijsen J; Bal M; De Jaeger K; Schuring D; Theuws J
    Radiother Oncol; 2011 Sep; 100(3):396-401. PubMed ID: 21955663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
    Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
    Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
    van Elmpt W; De Ruysscher D; van der Salm A; Lakeman A; van der Stoep J; Emans D; Damen E; Öllers M; Sonke JJ; Belderbos J
    Radiother Oncol; 2012 Jul; 104(1):67-71. PubMed ID: 22483675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer.
    Register SP; Zhang X; Mohan R; Chang JY
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1015-22. PubMed ID: 20615629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypofractionated stereotactic radiotherapy for medically inoperable stage I non-small cell lung cancer--report on clinical outcome and dose to critical organs.
    Ng AW; Tung SY; Wong VY
    Radiother Oncol; 2008 Apr; 87(1):24-8. PubMed ID: 18334273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study.
    van Baardwijk A; Bosmans G; Boersma L; Wanders S; Dekker A; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1394-401. PubMed ID: 18258380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
    Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer.
    Sekine I; Sumi M; Ito Y; Horinouchi H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kubota K; Tamura T
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):953-9. PubMed ID: 21377282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
    Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
    Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
    Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
    Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
    Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of geometrical uncertainties on 3D CRT and IMRT dose distributions for lung cancer treatment.
    Schwarz M; Van der Geer J; Van Herk M; Lebesque JV; Mijnheer BJ; Damen EM
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1260-9. PubMed ID: 16798418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced non-small cell lung cancer.
    Li BS; Gong HY; Huang W; Yi Y; Yu JM; Wang ZT; Zhang ZC; Sun HF; Li HS; Wang LY
    Am J Clin Oncol; 2012 Apr; 35(2):115-9. PubMed ID: 21555933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.